Anzeige
Mehr »
Donnerstag, 26.06.2025 - Börsentäglich über 12.000 News
TAO +1.800?%, SBAR +85?%, CYK +280?% - jetzt startet KORA auf Unternehmensebene durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DZJ0 | ISIN: US44148G2049 | Ticker-Symbol:
NASDAQ
25.06.25 | 22:00
1,190 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
HOTH THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
HOTH THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur HOTH THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiSilo Pharma, Hoth Therapeutics Enter LOI to Develop Obesity Treatment1
HOTH THERAPEUTICS Aktie jetzt für 0€ handeln
MiHoth Therapeutics, Inc: Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market212NEW YORK, June 25, 2025 - (ACN Newswire) - Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery...
► Artikel lesen
MiSilo Pharma to form JV with Hoth Therapeutics for obesity treatment1
MiSilo Pharma and Hoth Therapeutics plan joint venture for obesity treatment2
MiHoth Therapeutics, Silo Pharma Launch JV To Commercialize VA-Invented Obesity Drug-
MiHoth und Silo gründen Joint Venture für VA-lizenzierte Adipositas-Behandlung1
MiSilo Pharma, Inc.: Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market125Technology Co-Developed by the U.S. Department of Veterans Affairs and Emory University NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a developmental...
► Artikel lesen
DiHoth Therapeutics' Topical Gel Shows Promise In Mitigating Cancer Treatment Related Skin Problems1
DiHoth Therapeutics stock rises after positive Phase 2a trial results6
DiHoth Therapeutics, Inc.: Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects46Hoth Therapeutics' HT-001 Achieves 100% Response Rate in at least one endpoint in Phase 2a Trial in PK Patients for EGFR Inhibitor-Related Skin Toxicities. Hoth...
► Artikel lesen
FrHoth Therapeutics, Inc. - 8-K, Current Report2
18.06.Hoth Therapeutics regains Nasdaq compliance after meeting minimum bid1
18.06.Hoth Therapeutics, Inc.: Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth101NEW YORK, June 18, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on breakthrough therapies...
► Artikel lesen
18.06.Hoth Therapeutics reports positive preclinical safety data for HT-KIT3
18.06.Hoth Therapeutics, Inc.: Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway92HOTH ALERT: Hoth Therapeutics Reports Positive Preclinical Safety Data for HT-KIT - Dose-Dependent Activity, No Toxicity, IND on Deck HOTH announces strong preclinical...
► Artikel lesen
11.06.Hoth Therapeutics plans expanded access program for cancer skin toxicity drug5
11.06.Hoth Therapeutics plant Expanded-Access-Programm für Medikament gegen Hauttoxizität bei Krebstherapien5
11.06.Hoth Therapeutics, Inc.: Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities201Premier Research to support submission of an Expanded Access Program (EAP) application. This move positions Hoth to offer compassionate access to HT-001 for cancer...
► Artikel lesen
09.06.Hoth Therapeutics, Inc. - 8-K, Current Report1
05.06.Hoth Therapeutics advances with HT-001 oncology skin care treatment3
Weiter >>
68 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1